Small cell lung cancer data study using tumor and blood samples
Part of Cancer, Lungs & breathing clinical trials.
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have small cell lung cancer confirmed by biopsy (sample removed with a needle or surgery).
- Your cancer stage at diagnosis is extensive stage (for example, metastatic disease or very widespread chest disease).
- You can provide a tumor tissue sample as instructed (timing depends on whether you’re before or after first-line treatment).
- Your day-to-day function is good enough (ECOG 0–2, meaning you’re able to care for yourself and do light activities).
- If you join before first treatment, your planned first treatment is chemo (etoposide + platinum) plus a PD-L1 medicine (atezolizumab or durvalumab).
- You agree to consent and can share blood samples; palliative radiation is allowed if there’s measurable disease outside the radiation area.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study will follow people with advanced small cell lung cancer to learn more about how different treatments work in the real world. It may help doctors understand what helps patients live longer and feel better.
This trial collects blood and tumor samples from people newly diagnosed with small cell lung cancer to study how genetic markers can predict treatment success and monitor disease over time.
This study looks at immune-related blood/tissue markers to understand disease activity in people with extensive-stage small cell lung cancer after standard upfront treatment. If your cancer fits the pattern they’re studying, it may help researchers improve how future treatments are matched to patients.
This study collects tissue (and follows patients over time) to better understand the natural course of several types of chest cancers. It may help researchers learn which tests and treatments work best in different cancer types.
This Phase 2 trial tests how well two study drugs (and a combination of them) work in people with extensive-stage small cell lung cancer. It’s mainly for patients whose cancer has come back or who couldn’t tolerate at least some standard treatments, and it aims to see if treatment can shrink tumors and be tolerable.
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.